Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...
Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...
As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results